Three-dimensional conformal postoperative radiotherapy in patients with parotid tumors: 10 years’ experience at the European Institute of Oncology

Daniela Alterio1, Barbara A Jereczek-Fossa1,2, Mara Griseri1, Alberto D’Onofrio3, Gioacchino Giugliano4, Maria R Fiore1, Viviana Vitolo1, Piero Fossati1,2, Gaia Piperno1, Luca S Calabrese4, Elena Verri5, Fausto G Chiesa4, and Roberto Orecchia1,2

1Division of Radiation Oncology, European Institute of Oncology, Milan; 2University of Milan, Milan; 3Division of Experimental Oncology, 4Division of Head and Neck Surgery, and 5Division of Medical Oncology, European Institute of Oncology, Milan, Italy

ABSTRACT

Aims and background. Salivary gland malignancies are rare. The aim of our study was to investigate radiotherapy-related toxicity and clinical outcome in patients treated at our division with postoperative radiotherapy (pRT) for parotid tumors.

Methods and study design. Forty-three consecutive patients (32 with primary parotid tumors, 9 with parotid metastases and 2 with recurrent benign diseases) were retrospectively analyzed.

Results. The median follow-up was 28 months. Twenty and 5 patients had a follow-up longer than 2 and 5 years, respectively. Thirty-seven patients were alive and most of them (78%) were free from disease. The local and distant control rates were higher in patients with primary parotid tumors (94% and 87.5%) than in patients with parotid metastases (87.5% and 75%). Grade 3 radiotherapy-related acute toxicity of skin and mucosa was recorded in 20.9% and 28% of patients, respectively. Two patients (4.7%) had grade 4 skin toxicity. Late toxicity data were available for 33 (77%) patients. None of the patients developed severe (grade 3 and 4) late toxicity of soft tissues, skin or temporomandibular joints.

Conclusions. Postoperative radiotherapy is a feasible treatment that was found to be effective mainly in patients with primary parotid tumors. Toxicity was acceptable but could probably be further reduced using more advanced radiotherapy techniques. Longer follow-up is required to achieve definitive results.

Key words: parotid tumor, postoperative radiotherapy, toxicity, adjuvant treatment.

Acknowledgments: The authors would like to thank Giuseppe San- guineti, MD, for reviewing the manuscript.

Conflict of interest statement: No financial or other relationships that might lead to a conflict of interest are present.

Correspondence to: Daniela Alterio, MD, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. Tel +39-02-57489037; fax +39-02-94379227; e-mail Daniela.alterio@ieo.it

Received August 25, 2009; accepted October 16, 2009.